H.C. Wainwright 24th Annual Global Investment Conference
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...
Read More
CLINUVEL Kommuniqué IV
Seit dem letzten News Communiqué vom 23. Juni hat CLINUVEL die Entwicklung...
Read More
CLINUVEL Communiqué IV
Melbourne, Australia, 23 August 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
CLINUVEL Kommuniqué III
Seit dem News Communiqué II vom 31. März 2022 hat das Unternehmen...
Read More
CLINUVEL Communiqué III
Since News Communiqué II on 31 March 2022, the Company has reported...
Read More
Jeffries Healthcare Conference June 2022
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the Jeffries Healthcare...
Read More
H.C. Wainwright Global Investment Conference 2022
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...
Read More
Strategic Update IV
CLINUVEL today announced its fourth Strategic Update, focused on the Group’s view...
Read More
ACTH Manufacturing Update
CLINUVEL is progressing scaled manufacturing of adrenocorticotropic hormone (ACTH) under current Good...
Read More